PE20201346A1 - Constructos de fusion de anticuerpos que se acoplan a celulas nk - Google Patents

Constructos de fusion de anticuerpos que se acoplan a celulas nk

Info

Publication number
PE20201346A1
PE20201346A1 PE2020001584A PE2020001584A PE20201346A1 PE 20201346 A1 PE20201346 A1 PE 20201346A1 PE 2020001584 A PE2020001584 A PE 2020001584A PE 2020001584 A PE2020001584 A PE 2020001584A PE 20201346 A1 PE20201346 A1 PE 20201346A1
Authority
PE
Peru
Prior art keywords
antigen
cells
cd16a
coupled
binding
Prior art date
Application number
PE2020001584A
Other languages
English (en)
Spanish (es)
Inventor
Kristina Ellwanger
Ivica Fucek
Uwe Reusch
Thorsten Ross
Joachim Koch
Erich Rajkovic
Martin Treder
Michael Tesar
Original Assignee
Affimed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed Gmbh filed Critical Affimed Gmbh
Publication of PE20201346A1 publication Critical patent/PE20201346A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PE2020001584A 2018-04-13 2019-04-12 Constructos de fusion de anticuerpos que se acoplan a celulas nk PE20201346A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18167385 2018-04-13
EP18167384 2018-04-13
EP18190661 2018-08-24
EP18190662 2018-08-24
PCT/IB2019/053040 WO2019198051A2 (en) 2018-04-13 2019-04-12 Nk cell engaging antibody fusion constructs

Publications (1)

Publication Number Publication Date
PE20201346A1 true PE20201346A1 (es) 2020-11-25

Family

ID=66625219

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001584A PE20201346A1 (es) 2018-04-13 2019-04-12 Constructos de fusion de anticuerpos que se acoplan a celulas nk

Country Status (21)

Country Link
US (3) US11001633B2 (enExample)
EP (1) EP3774914A2 (enExample)
JP (2) JP2021521275A (enExample)
KR (1) KR20200143436A (enExample)
CN (3) CN113880952A (enExample)
AU (2) AU2019252970A1 (enExample)
BR (1) BR112020020828A2 (enExample)
CA (1) CA3095373A1 (enExample)
CL (2) CL2020002625A1 (enExample)
CO (1) CO2020014167A2 (enExample)
CR (1) CR20200549A (enExample)
IL (1) IL277925A (enExample)
MA (1) MA52227A (enExample)
MX (1) MX2020010728A (enExample)
PE (1) PE20201346A1 (enExample)
PH (1) PH12020551664B1 (enExample)
RU (1) RU2022105827A (enExample)
SG (1) SG11202010064QA (enExample)
TW (1) TW202012441A (enExample)
WO (1) WO2019198051A2 (enExample)
ZA (1) ZA202006325B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115066274A (zh) * 2019-09-25 2022-09-16 斯图加特大学 三价结合分子
EP4073117A1 (en) * 2019-12-10 2022-10-19 Institut Pasteur New antibody blocking human fcgriiia and fcgriiib
GB201919058D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
AU2020414409A1 (en) 2019-12-27 2022-06-16 Affimed Gmbh Method for the production of bispecific FcyRIIl x CD30 antibody construct
JP7620780B2 (ja) * 2020-06-30 2025-01-24 ノナ・バイオサイエンシーズ・（シャンハイ）・カンパニー・リミテッド Ｈ２Ｌ２とＨＣＡｂ構造を有する結合タンパク質
CN116368154A (zh) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
WO2022098972A1 (en) * 2020-11-08 2022-05-12 Seagen Inc. Combination-therapy antibody drug conjugate with immune cell inhibitor
US20250277024A1 (en) * 2020-12-03 2025-09-04 Amgen Inc. Molecules with multiple binding domains
JP2024503933A (ja) * 2021-01-27 2024-01-29 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド Ｃｄ１６ａに対する単一ドメイン抗体およびその使用
WO2022232503A1 (en) 2021-04-30 2022-11-03 Genentech, Inc. Therapeutic and diagnostic methods and compositions for cancer
CA3216098A1 (en) 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
JP2024529494A (ja) * 2021-07-30 2024-08-06 クレ バイオテクノロジ （シャンハイ） カンパニー リミテッド 抗原ターゲティング、抗ｃｄ１６ａおよび免疫エフェクター細胞活性化の三機能性融合タンパク質ならびにその応用
CN113929785B (zh) * 2021-09-10 2023-05-23 钦元再生医学(珠海)有限公司 一种可自分泌pd1-trem2双特异性抗体的嵌合抗原受体免疫细胞及其应用
EP4405379A4 (en) * 2021-09-24 2025-08-20 Synergy Imt Inc COMPOSITION OF RECOMBINANT ANTIGEN-BINDING MOLECULES AND METHOD OF MANUFACTURE AND USE THEREOF
US20260070986A1 (en) 2021-11-03 2026-03-12 Affimed Gmbh Bispecific cd16a binders
IL312515A (en) 2021-11-03 2024-07-01 Affimed Gmbh Bispecific cd16a binders
CN116284385A (zh) * 2021-12-07 2023-06-23 信达细胞制药(苏州)有限公司 靶向bcma的p329g抗体及其与嵌合抗原受体细胞的组合和应用
CN114349869B (zh) * 2021-12-20 2023-09-26 上海恩凯细胞技术有限公司 一种双特异性的nk细胞激动剂及制备方法和应用
CN119923415A (zh) * 2022-08-05 2025-05-02 成都恩沐生物科技有限公司 靶向可二聚化肿瘤抗原和免疫刺激性抗原的多特异性抗体
CN120035609A (zh) * 2022-09-14 2025-05-23 大塚制药株式会社 Pd-1激动剂抗体
CN120641128A (zh) * 2023-02-06 2025-09-12 乐普创一生物科技（上海）有限公司 抗cd16a抗体及其用途
KR20240136856A (ko) * 2023-03-06 2024-09-19 주식회사 드노보 바이오테라퓨틱스 신규한 항-cd16 항체 및 이의 용도
WO2025257588A1 (en) * 2024-06-10 2025-12-18 Affimed Gmbh Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2002066516A2 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
MX341884B (es) 2009-03-10 2016-09-07 Biogen Ma Inc Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
EP2361936B1 (en) * 2010-02-25 2016-04-20 Affimed GmbH Antigen-binding molecule and uses thereof
KR101972446B1 (ko) 2011-05-27 2019-04-25 글락소 그룹 리미티드 Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）­결합 단백질
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EP2825557B1 (en) 2012-03-16 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Soluble engineered monomeric fc
CN104736174B (zh) * 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
WO2014068079A1 (en) 2012-11-01 2014-05-08 Max-Delbrück-Centrum für Molekulare Medizin An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
WO2014122143A1 (en) 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
JP2016514676A (ja) * 2013-03-15 2016-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 四価二重特異性抗体
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
RU2016132863A (ru) * 2014-01-15 2018-02-20 Займворкс Инк. БИСПЕЦИФИЧЕСКИЕ CD3 и CD19 АНТИГЕНСВЯЗЫВАЮЩИЕ КОНСТРУКЦИИ
CA3138083A1 (en) * 2014-12-22 2016-06-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
CA2973720A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
LT3292153T (lt) * 2015-05-04 2019-11-11 Affimed Gmbh Cd30xcd16a antikūno derinys su antagonistiniu antikūnu prieš pd-1 skirtas terapijai
EP3091031A1 (en) * 2015-05-04 2016-11-09 Affimed GmbH Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor
AU2016284871B2 (en) * 2015-06-23 2022-09-29 Innate Pharma Multispecific NK engager proteins
MX2018002043A (es) * 2015-08-17 2018-07-06 Janssen Pharmaceutica Nv ANTICUERPOS ANTI-BCMA, MOLí‰CULAS DE UNIí“N A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS.
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
CN105367660B (zh) * 2015-12-22 2018-12-21 深圳市北科生物科技有限公司 一种抗cd16a抗原和抗muc1抗原的双特异性抗体
CN106632681B (zh) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 抗egfr和抗cd3双特异抗体及其应用
WO2018158349A1 (en) * 2017-02-28 2018-09-07 Affimed Gmbh Tandem diabody for cd16a-directed nk-cell engagement

Also Published As

Publication number Publication date
CO2020014167A2 (es) 2021-04-08
WO2019198051A3 (en) 2019-11-14
PH12020551664A1 (en) 2021-12-13
CN113880952A (zh) 2022-01-04
ZA202006325B (en) 2025-12-17
US20210253698A1 (en) 2021-08-19
SG11202010064QA (en) 2020-11-27
MX2020010728A (es) 2020-11-06
AU2026200541A1 (en) 2026-02-19
CA3095373A1 (en) 2019-10-17
BR112020020828A2 (pt) 2021-01-19
AU2019252970A1 (en) 2020-11-26
CN112119097B (zh) 2021-10-15
PH12020551664B1 (en) 2023-05-19
WO2019198051A2 (en) 2019-10-17
CL2023001085A1 (es) 2023-10-06
US20240294647A1 (en) 2024-09-05
US11001633B2 (en) 2021-05-11
MA52227A (fr) 2021-04-21
CN113817066A (zh) 2021-12-21
CR20200549A (es) 2021-03-18
RU2022105827A (ru) 2022-04-05
CL2020002625A1 (es) 2021-02-19
KR20200143436A (ko) 2020-12-23
JP2025081307A (ja) 2025-05-27
JP2021521275A (ja) 2021-08-26
IL277925A (en) 2020-11-30
US20200109202A1 (en) 2020-04-09
TW202012441A (zh) 2020-04-01
EP3774914A2 (en) 2021-02-17
CN112119097A (zh) 2020-12-22

Similar Documents

Publication Publication Date Title
PE20201346A1 (es) Constructos de fusion de anticuerpos que se acoplan a celulas nk
MX2022006760A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
CL2019001001A1 (es) Proteínas de fusión heterodiméricas biespecificas que contienen proteínas de fusión fc il-15/il-15ralfa y fragmentos de anticuerpo pd-1.
CY1120849T1 (el) Αντισωμα που συνδεεται σε ανθρωπινο cd3
MX2020013631A (es) Variantes de anticuerpo grupo de diferenciacion (cd38) y usos de las mismas.
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
EA201991912A1 (ru) Составы, содержащие pd-1-связывающие белки, и способы их получения
MX2021011330A (es) Anticuerpos de claudina-6 y conjugados de fármacos.
EA202191105A1 (ru) Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
AU2015269210A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
WO2014144542A3 (en) Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
MX360746B (es) Anticuerpos que comprenden dominios constantes quiméricos.
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
JP2016526909A5 (enExample)
MX387560B (es) Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
AR114102A1 (es) Anticuerpo biespecífico heterodimérico estructural natural anti-pd-1 / anti-her2 y método para su preparación
MX2021000788A (es) Composiciones de anticuerpos del receptor de fc (fcrn).
MY198370A (en) Proteins specific for baff and b7rp1
MX2020011529A (es) Un metodo para optimizar la expresion de anticuerpos.
EA201791918A1 (ru) Модификация белков клеток-хозяев
MX2017010359A (es) Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc).
PE20100695A1 (es) Proteina vegetal hibrida y metodo para obtener la misma
EA201990822A1 (ru) Иммуномодулирующие слитые белки
EA201691548A1 (ru) Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды